Diabetes Market Research Reports & Industry Analysis

... term: battle lines are drawn The fundamental drivers of the global diabetes market are strong and continue to fuel growth. Rising levels ... comprehensive FirstWord research is available in two comprehensive modules: The KOL Insight: Diabetes module provides a complete review and is enhanced with exclusive ...

... diabetes care. “UAE Diabetes Market Opportunity Analysis 2018” gives comprehensive insight on following aspects related to pharmaceutical market: Market Overview Diabetes Prevalence Diabetes Drug Market Insulin Delivery Devices Market Glucose Monitoring Devices Market Diabetes Market ...

... to reach approximately US$ 4.6 Billion by 2018. In RNCOS’ latest report “China Diabetes Market Outlook 2018”, the country’s diabetes market has been segmented ... been extending their product portfolios in order to gain their own market shares. In the end, RNCOS concludes with a competitive analysis of major ...

Takeda’s late stage pipeline candidate – Vortioxetine (Filed, Partnered with Lundbeck, US PDUFA on October 2nd) is expected to get ... present an attractive market for new entrants. Reported PhIII data of Vortioxetine look. However, other pipeline candidates are chasing ...

... ; Novo Nordisk) recent US failure, the exponential market growth makes diabetes one of the most attractive opportunities in Pharma. Competition in the major ... market share from the gold standard treatments. ‘Therapy Trends: Diabetes’ is compiled from exclusive, in-depth interviews with the world’s leading ...

... run in January looking at physician detailing, this week’s FirstWord Physician Views poll investigates which companies are best at physician marketing in the diabetes space. Notably, failure to gain ... endocrinologists, which are the best detailing diabetes companies and drugs and what factors support this view. This week's FirstWord Physician Views poll will ...

... to extend and enhance its market-leading Lantus franchise. At the ADA meeting, Sanofi released the first Phase III data for ... patent expiry date is feasible. In light of recent developments, this week’s Physician Views poll will ask US-based endocrinologists: Whether they anticipate data ...

... of pharmaceutical manufacturers, this week's Physician Views poll will seek feedback from US-based endocrinologists on three key recent developments – discussion regarding pancreatic cancer/pancreatitis ... Physicians View poll will ask US-based endocrinologists: How their prescribing of DPP-4 and GLP-1 products may shift in light of the FDA’s recent assessment ...

... growth rates in the more developed markets have declined. IMARC’s new report “Indian Diabetes Market Report: Epidemiology, Patients, Prevalence, Oral Anti- ... , demographical breakup, diagnosis and treatment of diabetes in India. The report has segmented the Indian diabetes market into three segments

... refractory patients– each of these segments carries ~$1b opportunity to Takeda. In this report, we have analyze TAK-875 market positioning and model, target segments, therapy ...

Turn of The Decade: Novel Glp-1’s To Emerge as the New Leader in Diabetes Class Bydureon – A near term growth driver of the class Novel delivery platforms and fixed ... in cumulative peak sales for this class of drugs by the turn of this decade as we see innovation efforts around this class will result in ...

Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,200.00 Hard Copy: US$ 900.00 CD-ROM: US$ 900.00 Diabetes has emerged as one of the most common diseases in China, affecting...

IMARC’s new report “Japan Diabetes Market Report & Forecast 2011-2016” provides an analytical and statistical insight into the Japanese diabetes market. The report provides both current and future tre...

Product description The present Competitive Intelligence Report about Targeted Therapy of Diabetes provides a competitor evaluation in the field of novel molecules being developed for treatment of type 1 and 2 diabetes as of April 2011. Major pharmacologic approaches include insulin, PPAR agonists, DPP-IV ...

Single User PDF Format: US$ 800.00 Multi-User License: US$ 1,200.00 Hard Copy: US$ 900.00 CD-ROM: US$ 900.00 Diabetes is the world’s most costly epidemic. It is anticipated that, over...

As the second largest economy of the world, China enjoys pink of health but its affluence is giving rise to another sickness- a rapid increase in a life-style disease called diabetes. With the Chinese...

With around 51 Million diabetes patients, India promises to be amongst the most lucrative diabetes markets in the world. In 2009, the total sales of Insulin and Non-Insulin Anti-diabetics reached US$...

Diabetic gastroparesis is a chronic gastrointestinal complication that occurs when long-term diabetes damages the vague nerve, impairing the stomach’s ability to empty its contents at a normal rate. T...

Diabetic kidney disease (DKD), also known as diabetic nephropathy, is a chronic complication of diabetes that affects the kidneys’ ability to filter waste from the blood effectively. It is characteriz...

Diabetic Macular Edema is a severe ocular complication of diabetes mellitus, characterized by fluid accumulation in the macula the central portion of the retina responsible for sharp, detailed vision....

Diabetic neuropathic pain is a common and serious complication of diabetes that arises from chronic nerve damage caused by prolonged high blood sugar levels. It primarily affects the peripheral nervou...